NLM Digital Collections

Search

Search Constraints

Start Over You searched for: Subjects Research Design Remove constraint Subjects: Research Design

Search Results

1. ACA state based marketplace public reporting: comparing open enrollment period 1 (OEP1) to open enrollment period 2 (OEP2)

4. BCG-unresponsive nonmuscle invasive bladder cancer: developing drugs and biologics for treatment

5. Duchenne muscular dystrophy and related dystrophinopathies: developing drugs for treatment

7. E6(R2) good clinical practice: integrated addendum to ICH E6(R1)

9. S3A guidance: note for guidance on toxicokinetics : the assessment of systemic exposure in toxicity studies : focus on microsampling : questions and answers

10. Establishing effectiveness for drugs intended to treat male hypogonadotropic hypogonadism attributed to nonstructural disorders

11. Anthrax: developing drugs for prophylaxis of inhalational anthrax

12. S9 nonclinical evaluation for anticancer pharmaceuticals: questions and answers

15. Allergic rhinitis: developing drug products for treatment

64. Evaluation of Will Power/Won't Power in Los Angeles County: final impact report for Volunteers of America--Girls Inc. of Greater Los Angeles : findings from an innovative teen pregnancy prevention program, October 31, 2015 : submitted with revisions on May 6, 2016

65. Evaluation of Youth All Engaged (YAE) in Denver, CO: final impact report for Denver Public Health : findings from an innovative teen pregnancy prevention program

69. E14 clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs--questions and answers (R3)

70. Evaluation and reporting of age-, race-, and ethnicity-specific data in medical device clinical studies: guidance for Industry and Food and Drug Administration staff

71. Establishing the performance characteristics of in vitro diagnostic devices for the detection or detection and differentiation of human papillomaviruses: guidance for Industry and Food and Drug Administration staff

72. Requests for feedback on medical device submissions: the pre-submission program and meetings with Food and Drug Administration staff : guidance for industry and Food and Drug Administration staff

73. General principles for evaluating the abuse deterrence of generic solid oral opioid drug products

75. Separating fact from fiction: recommendations for academic health centers on artificial and augmented intelligence

76. Calculation of outcome rates that diagnose bedside performance: central-line-associated bloodstream infection

78. Meta-analysis of federally funded teen pregnancy prevention programs: technical supplement

79. Meta-analysis of federally funded teen pregnancy prevention programs: final report

82. Considerations for building federal data capacity for patient-centered outcomes research related to intellectual and developmental disabilities

83. Enrichment strategies for clinical trials to support determination of effectiveness of human drugs and biological products

84. Considerations in demonstrating interchangeability with a reference product

86. Delayed graft function in kidney transplantation: developing drugs for prevention

90. Osteoporosis: nonclinical evaluation of drugs intended for treatment

91. Consideration of uncertainty in making benefit-risk determinations in medical device premarket approvals, de novo classifications, and humanitarian device exemptions: guidance for industry and Food and Drug Administration staff

92. Investigational enzyme replacement therapy products: nonclinical assessment

93. Smallpox (variola virus) infection: developing drugs for treatment or prevention

94. Adaptive designs for clinical trials of drugs and biologics

97. Linking state Medicaid data and birth certificates for maternal health research

98. Assessing the usability of encounter data for enrollees in comprehensive managed care 2010-2011